Study shows biocept's target selector™ detects mutations in “quantity not sufficient” specimens in non-small cell lung cancer patients

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, will present data showing that its target selector™ molecular assay kit detects mutations in up to 50% of tissue biopsy specimens, from patients diagnosed with non-small cell lung cancer, that were deemed quantity not sufficient (qns). the study will be presented at the molecular med tri-con virtual conference, feb. 16-18, 2021. molecular testing of biopsy specimen
BIOC Ratings Summary
BIOC Quant Ranking